GETTING MY MBL77 TO WORK

mutations, in whom rituximab seems to acquire minimal added value.59 Other genomic subgroups, for example individuals with BIRC3Reworked DLBCL usually incorporate CDKN2A deletions and MYC translocations or amplifications along with the genomic alterations by now present in the first CLL, but lack the frequent mutations observed in Main DLBCL indica